Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 7Myeloproliferative Disorders 3Recurrence 2Myelodysplastic Syndromes 2Hematologic Neoplasms 2Glioma 2Cholangiocarcinoma 2Pancreatic Ductal Adenocarcinoma 1Leukemia 1IDH1-Mutated Malignancies 1IDH1 Mutation Myeloid Neoplasms 1Chondrosarcoma 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × ivosidenib × Clear all
NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Servier

Phase 1 Recruiting
291 enrolled 3 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡